Combination Immunotherapy with 4-1BBL and CTLA-4 Blockade for the Treatment of Prostate Cancer
Immune regulation has been shown to be involved in the progressive growth of some murine tumours. Interruption of immune regulatory pathways via activation of 4-1BB or cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) blockade appears to be a promising strategy for cancer immunotherapy. In this s...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Clinical and Developmental Immunology |
| Online Access: | http://dx.doi.org/10.1155/2012/439235 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832558745376260096 |
|---|---|
| author | Kuang Youlin Zhang Li Weng Xiaodong Liu Xiuheng Zhu Hengchen |
| author_facet | Kuang Youlin Zhang Li Weng Xiaodong Liu Xiuheng Zhu Hengchen |
| author_sort | Kuang Youlin |
| collection | DOAJ |
| description | Immune regulation has been shown to be involved in the progressive growth of some murine tumours. Interruption of immune regulatory pathways via activation of 4-1BB or cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) blockade appears to be a promising strategy for cancer immunotherapy. In this study, we examined the effectiveness of 4-1BBL-expressing tumor cell vaccine in combination with CTLA-4 blockade on rejection of murine prostate cancer RM-1. We found that the combination of both a vaccine consisting of 4-1BBL-expressing RM-1 cells and CTLA-4 blockade resulted in regression of RM-1 tumors and a significant increase in survival of the tumour cell recipients, compared to that of either treatment alone. The combined vaccination resulted in higher CTL against RM-1 cells and increased secretion of IFN-, TNF- and IL-2 in the mix-cultured supernatant. These results suggest that combining activation of 4-1BB and blockade of CTLA-4 may offer a new strategy for prostate cancer immunotherapy. |
| format | Article |
| id | doaj-art-a25868494fbe4abb9bc6815592111a76 |
| institution | Kabale University |
| issn | 1740-2522 1740-2530 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Developmental Immunology |
| spelling | doaj-art-a25868494fbe4abb9bc6815592111a762025-02-03T01:31:47ZengWileyClinical and Developmental Immunology1740-25221740-25302012-01-01201210.1155/2012/439235439235Combination Immunotherapy with 4-1BBL and CTLA-4 Blockade for the Treatment of Prostate CancerKuang Youlin0Zhang Li1Weng Xiaodong2Liu Xiuheng3Zhu Hengchen4Renmin Hospital of Wuhan University, Wuhan 430060, ChinaRenmin Hospital of Wuhan University, Wuhan 430060, ChinaRenmin Hospital of Wuhan University, Wuhan 430060, ChinaRenmin Hospital of Wuhan University, Wuhan 430060, ChinaRenmin Hospital of Wuhan University, Wuhan 430060, ChinaImmune regulation has been shown to be involved in the progressive growth of some murine tumours. Interruption of immune regulatory pathways via activation of 4-1BB or cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) blockade appears to be a promising strategy for cancer immunotherapy. In this study, we examined the effectiveness of 4-1BBL-expressing tumor cell vaccine in combination with CTLA-4 blockade on rejection of murine prostate cancer RM-1. We found that the combination of both a vaccine consisting of 4-1BBL-expressing RM-1 cells and CTLA-4 blockade resulted in regression of RM-1 tumors and a significant increase in survival of the tumour cell recipients, compared to that of either treatment alone. The combined vaccination resulted in higher CTL against RM-1 cells and increased secretion of IFN-, TNF- and IL-2 in the mix-cultured supernatant. These results suggest that combining activation of 4-1BB and blockade of CTLA-4 may offer a new strategy for prostate cancer immunotherapy.http://dx.doi.org/10.1155/2012/439235 |
| spellingShingle | Kuang Youlin Zhang Li Weng Xiaodong Liu Xiuheng Zhu Hengchen Combination Immunotherapy with 4-1BBL and CTLA-4 Blockade for the Treatment of Prostate Cancer Clinical and Developmental Immunology |
| title | Combination Immunotherapy with 4-1BBL and CTLA-4 Blockade for the Treatment of Prostate Cancer |
| title_full | Combination Immunotherapy with 4-1BBL and CTLA-4 Blockade for the Treatment of Prostate Cancer |
| title_fullStr | Combination Immunotherapy with 4-1BBL and CTLA-4 Blockade for the Treatment of Prostate Cancer |
| title_full_unstemmed | Combination Immunotherapy with 4-1BBL and CTLA-4 Blockade for the Treatment of Prostate Cancer |
| title_short | Combination Immunotherapy with 4-1BBL and CTLA-4 Blockade for the Treatment of Prostate Cancer |
| title_sort | combination immunotherapy with 4 1bbl and ctla 4 blockade for the treatment of prostate cancer |
| url | http://dx.doi.org/10.1155/2012/439235 |
| work_keys_str_mv | AT kuangyoulin combinationimmunotherapywith41bblandctla4blockadeforthetreatmentofprostatecancer AT zhangli combinationimmunotherapywith41bblandctla4blockadeforthetreatmentofprostatecancer AT wengxiaodong combinationimmunotherapywith41bblandctla4blockadeforthetreatmentofprostatecancer AT liuxiuheng combinationimmunotherapywith41bblandctla4blockadeforthetreatmentofprostatecancer AT zhuhengchen combinationimmunotherapywith41bblandctla4blockadeforthetreatmentofprostatecancer |